Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. (ALC) generates frequent news as a global eye care company listed on the SIX Swiss Exchange and the New York Stock Exchange. Company communications emphasize a long heritage in eye care, a broad Surgical and Vision Care portfolio, and a large international patient reach, which together make Alcon a regular subject of healthcare, medical device and capital markets coverage.
News about Alcon often highlights developments in its Surgical and Vision Care segments, including product launches and portfolio updates that address conditions such as cataracts, glaucoma, retinal diseases and refractive errors. The company has stated that it is advancing global launches of major products across these franchises, and such initiatives are typically announced through press releases and investor events.
Investors following ALC news can also expect updates on corporate strategy and transactions. For example, Alcon has reported on a definitive merger agreement with STAAR Surgical Company and later announced the termination of that agreement in a January 6, 2026 press release. These items appear in both company news and related regulatory filings, providing insight into how Alcon approaches acquisitions and refractive surgery strategy.
Coverage may further include Alcon’s participation in major healthcare conferences, where senior executives present the company’s outlook and discuss its Surgical and Vision Care businesses. Such events are typically accompanied by webcasts and formal announcements. By monitoring this news feed, readers can track key developments affecting Alcon’s product portfolio, strategic direction and presence in the global eye care market.
Alcon (SIX/NYSE: ALC) has launched SYSTANE PRO Preservative-Free (PF) in the U.S., its latest over-the-counter eye drop for dry eye relief. The product features a unique triple action, preservative-free formula that includes hyaluronate, nano-sized lipids, and HP-Guar, making it the longest-lasting eye drop in the SYSTANE portfolio.
The launch addresses a significant market need, as dry eye disease affects approximately 45.5 million people in the United States and 1.5 billion globally. SYSTANE PRO PF works by providing sustained hydration, restoring tear film stability, and protecting against further eye irritation. The product will be available in the U.S. starting this month, with expansion to additional markets planned for 2026.
SYSTANE is currently the #1 global consumer brand of artificial tears, and this new addition strengthens Alcon's position in the dry eye treatment market.
Alcon (ALC) announced the full U.S. commercial launch of Voyager DSLT, the first Direct Selective Laser Trabeculoplasty device for treating glaucoma and ocular hypertension. The automated device delivers 120 laser pulses without requiring a gonio lens, streamlining the treatment process for nearly 5 million Americans diagnosed with glaucoma.
Key features include an intuitive touchscreen interface and SureTrac eye-tracking technology for precise delivery. Clinical data shows that 62% of DSLT participants were medication-free at 12 months, and 92.5% would recommend the treatment to others. The device will be showcased at the 2025 American Glaucoma Society meeting in Washington, D.C.
This launch expands Alcon's glaucoma portfolio, which includes Hydrus Microstent, EX-PRESS Glaucoma Filtration Device, and pharmaceutical drops.
Alcon (SIX/NYSE: ALC) has announced that CEO David Endicott will present at the 2025 J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 p.m. PST. The presentation will be available via live webcast on the company's investor relations website.
Alcon, the global leader in eye care with a 75+ year heritage, serves over 260 million people annually across 140+ countries through their Surgical and Vision Care products. The company focuses on treating conditions including cataracts, glaucoma, retinal diseases, and refractive errors. With more than 25,000 associates, Alcon works to enhance quality of life through innovative products, partnerships with Eye Care Professionals, and programs advancing access to quality eye care.
Alcon (ALC) reported strong Q3 2024 results with sales of $2.4 billion, up 6% year-over-year. The company achieved diluted EPS of $0.53, a 29% increase, and core diluted EPS of $0.81, up 23%. Notable performance includes record free cash flow of $1.3 billion, up 119% in the first nine months. Surgical segment sales reached $1.3 billion (+5%), while Vision Care segment hit $1.1 billion (+7%). The company generated $1.6 billion in operating cash flows and updated its 2024 outlook, projecting net sales between $9.8-9.9 billion with core diluted EPS of $3.00-3.05.
Alcon (ALC) has launched PRECISION7, a revolutionary one-week replacement contact lens in the U.S. The lens features the world's first ACTIV-FLO System, providing 16 hours of comfort and precise vision through day 7. This innovation addresses affordability concerns, as over half of new patients opt for reusable lenses despite ECPs preferring daily disposables. PRECISION7 will be available through select ECPs immediately, with broader U.S. commercial availability in January 2025. The product launches with both sphere and toric lenses simultaneously, featuring a unique moisturizing system that combines water-loving agents and proprietary replenishing technology.
Alcon Singapore has been recognized as one of the 'Best Employers in Singapore' for three years (2021, 2023, and 2024), achieving second place in the Health Care Equipment & Services Industry category. The recognition comes from a comprehensive survey by The Straits Times, where associates anonymously evaluate their willingness to recommend their company. Alcon Singapore focuses on three key areas: Diversity & Inclusion, Social Impact and Sustainability, and Talent Development. The company implements various programs including the 'Women Supporting Women' initiative, community engagement through 'Alcon in Action', and the upgraded 'Development In Action' program for associate growth.
Alcon (SIX/NYSE: ALC) will showcase its latest innovations at the American Academy of Ophthalmology (AAO) 2024 annual meeting. Key highlights include:
- The Voyager DSLT, a new first-line laser therapy for glaucoma patients
- New handheld gas delivery systems, UNIFEYE and UNIPEXY, for retina surgeons
- Pivotal data presentation for AR-15512 (acoltremon 0.003%), a dry eye treatment candidate under FDA review
Alcon's booth #4008 will offer hands-on demonstrations of these technologies. The company emphasizes its focus on improving patient outcomes and enhancing surgical efficiency. New clinical data on Alcon's surgical products will also be presented at the conference.
Horizon Sports & Experiences (HS&E) has announced Shark Beauty™ as the title sponsor for the inaugural Shark Beauty™ Women's Champions Classic, a primetime women's college basketball showcase. The event, scheduled for December 7 at Barclays Center in Brooklyn, will feature the University of Connecticut, University of Iowa, University of Louisville, and University of Tennessee in a doubleheader broadcast on FOX.
This collaboration between HS&E and FOX Sports marks a significant step in elevating women's college basketball. Shark Beauty™ will receive broadcast and digital integrations, sponsorship elements, hospitality, fan engagement activation, and in-arena signage as part of its multiyear partnership. The event aims to provide a national spotlight for women's basketball and introduce Shark Beauty to a wide audience of passionate fans.
Alcon (ALC) reported strong Q2 2024 results with record sales of $2.5 billion, up 3% (6% constant currency). Key highlights include:
- Diluted EPS of $0.45, up 32% (47% cc)
- Core diluted EPS of $0.74, up 7% (15% cc)
- H1 2024 cash from operations of $871 million
- Free cash flow of $667 million, up 253%
Growth was driven by robust demand for innovative products, balanced geographic footprint, and strong execution. Surgical sales increased 3% (6% cc) to $1.4 billion, with strength in international markets. Vision Care sales grew 4% (6% cc) to $1.1 billion, led by contact lenses. The company maintained its 2024 outlook, projecting 7-9% constant currency sales growth and core diluted EPS of $3.00-$3.10.
Alcon announced that its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) have received U.S. FDA 510(k) clearance. These systems are the first innovations from Alcon's Unity portfolio, aimed at transforming surgical procedures in ophthalmology. Alcon plans to gather real-world user feedback in the U.S. before a broad commercialization in 2025. The Unity systems are set to replace Alcon's current leading systems and introduce significant workflow efficiencies. Regulatory submissions will continue globally, with a CE Mark expected in early 2025.